HC Wainwright Reiterates “Buy” Rating for XOMA (NASDAQ:XOMA)

HC Wainwright restated their buy rating on shares of XOMA (NASDAQ:XOMA) in a research report report published on Friday morning, Benzinga reports. HC Wainwright currently has a $117.00 price objective on the biotechnology company’s stock.

Separately, StockNews.com raised shares of XOMA from a sell rating to a hold rating in a research report on Wednesday, August 14th.

XOMA Price Performance

XOMA stock opened at $27.09 on Friday. The company has a market cap of $315.30 million, a PE ratio of -6.91 and a beta of 0.93. The company has a current ratio of 8.71, a quick ratio of 8.71 and a debt-to-equity ratio of 1.15. The stock has a 50-day moving average price of $27.51 and a two-hundred day moving average price of $25.90. XOMA has a 12-month low of $13.48 and a 12-month high of $30.36.

XOMA (NASDAQ:XOMA) last issued its earnings results on Tuesday, August 13th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.02). The firm had revenue of $11.09 million for the quarter, compared to analysts’ expectations of $8.37 million. XOMA had a negative return on equity of 24.50% and a negative net margin of 128.59%. As a group, research analysts predict that XOMA will post -1.42 EPS for the current year.

Institutional Investors Weigh In On XOMA

A number of large investors have recently modified their holdings of XOMA. Bank of New York Mellon Corp grew its holdings in XOMA by 3.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 62,656 shares of the biotechnology company’s stock valued at $1,484,000 after purchasing an additional 1,968 shares in the last quarter. Rhumbline Advisers lifted its holdings in XOMA by 16.0% in the 2nd quarter. Rhumbline Advisers now owns 9,695 shares of the biotechnology company’s stock worth $230,000 after buying an additional 1,334 shares in the last quarter. Price T Rowe Associates Inc. MD purchased a new position in XOMA in the 1st quarter valued at about $212,000. Finally, BNP Paribas Financial Markets grew its stake in shares of XOMA by 55.6% during the first quarter. BNP Paribas Financial Markets now owns 3,543 shares of the biotechnology company’s stock valued at $85,000 after acquiring an additional 1,266 shares in the last quarter. Institutional investors and hedge funds own 95.92% of the company’s stock.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.